The Advertising Standards Authority (ASA) has taken decisive action by banning five advertisements for health supplements that made unsubstantiated claims about treating symptoms of menopause, polycystic ovarian syndrome (PCOS), and other women's hormonal conditions. This move follows an AI-powered sweep of online health claims, where the ASA identified numerous 'unacceptable' assertions that risked misleading vulnerable individuals.
Targeted Products and Unverified Claims
Among the prohibited products are 222 Balance Me, Lunera, Minerva, Nova Menopause Vitality, and PolyBiotics. These supplements were advertised with claims suggesting they could prevent, treat, or cure conditions like menopause and PCOS, which the ASA found to be lacking in scientific evidence. The authority emphasized that such marketing tactics could exploit people's health worries, particularly in the sensitive area of women's health.
Company Responses and Compliance Efforts
In response to the bans, some companies have acknowledged their missteps. 222 Collective, Lunera, and PolyBiotics have admitted that their claims were inappropriate and are now working to align their advertising with regulatory standards. However, Minerva and Nova did not engage with the ASA's enquiries, highlighting potential ongoing compliance issues.
The ASA has reiterated its commitment to closely monitoring the women's health sector to ensure that information provided to the public is clear and accurate. They encourage consumers to report any advertising concerns, reinforcing a proactive approach to safeguarding against misleading health claims.
